Navigation Links
Study finds some insulin production in long-term Type 1 diabetes
Date:2/21/2012

Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.

"Traditionally, it was thought that beta cell function completely ceased in patients with advanced type 1 diabetes. However, data from this study and others suggest that the pancreas continues to function at some level even decades after the onset of type 1 diabetes," says Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, who led the study.

In the current study, blood samples from 182 individuals with type 1 diabetes were evaluated using an ultrasensitive assay for C-peptide, a marker of insulin secretion, to test for residual beta cell function. The study revealed that C-peptide production can persist for decades after disease onset and remains functionally responsive to blood sugar levels. Although C-peptide levels were lower among those who had longer duration of diabetes, the decrease over time was gradual and not the abrupt decline predicted by the conventional picture of type 1 diabetes. Even among patients with disease duration of 31 to 40 years, 10 percent still produced C-peptide. In addition, beta cell functioning remained intact at very low C-peptide levels.

The novel assay which is 22 times more sensitive than the current standard also was able to detect C-peptide in 34 of 54 weekly blood samples from four participants in Faustman's trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type 1 diabetes, while the standard assay was unable to detect C-peptide in any of those samples. The researchers conclude that this ultrasensitive assay offers a novel approach to identify patients, even with advanced disease, who may benefit from treatments to retain or enhance beta cell function. They further note that patients with low C-peptide levels or advanced disease may benefit from new interventions to preserve or enhance beta cell function and prevent complications.

"Our results contribute to a growing body of evidence suggesting there might be a longer window for therapeutic intervention in this disease and also may help explain the transient restoration of insulin production we saw in patients who received BCG in our Phase I clinical trial," says Faustman, an associate professor of Medicine at Harvard Medical School.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Stronger intestinal barrier may prevent cancer in the rest of the body, new study suggests
2. Aspirin as Good as Plavix for Poor Leg Circulation: Study
3. Study: No Significant Rise in Seizure Risk From Common Kids Vaccine
4. Study: Brain makes call on which ear is used for cell phone
5. Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimers disease
6. Worries About Colonoscopy Unfounded: Study
7. Perception, work-life balance key factors in workplace safety, says UGA study
8. Kids With Crohns Disease, Colitis Often Struggle at School: Study
9. Exercise Can Build Young Adults Bones, Study Finds
10. Study documents the importance of supportive spouses in coping with work-related stress
11. Study evaluates faster treatment for seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology: